Takeda Pharmaceutical is a biopharmaceutical company. It develops and markets pharmaceutical products in oncology, rare genetics and hematology, neuroscience, and gastroenterology, as well as plasma-derived therapies and vaccines. Its products in the key business areas include the following brands: ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG.
Type | Public | |
Founded | 1781 | |
HQ | Tokyo, JP | Map |
Website | takeda.com | |
Employee Ratings | ||
Overall Culture | A | More |
JPY | |
---|---|
Revenue (Q3, 2022) | 901.3b |
Gross profit (Q3, 2022) | 781.9b |
Net income (Q3, 2022) | 57.8b |
EBITDA (Q3, 2022) | 380.1b |
EBIT (Q3, 2022) | 114.8b |
Market capitalization (13-May-2022) | 5.7t |
Closing stock price (13-May-2022) | 3.7k |
Cash (31-Dec-2021) | 724.3b |
EV | 9.3t |
JPY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Revenue | 1.8t | 2.1t | 3.3t | 3.2t |
Cost of goods sold | (313.8b) | (387.2b) | (506.1b) | (434.6b) |
Gross profit | 1.5t | 1.8t | 2.8t | 2.8t |
R&D expense | (325.4b) | (368.3b) | (492.4b) | (455.8b) |
JPY | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 449.8b | 430.8b | 499.4b | 849.1b | 811.0b | 859.3b | 801.9b | 788.9b | 836.8b | 949.6b | 844.8b | 901.3b |
Cost of goods sold | (82.0b) | (71.3b) | (100.2b) | (124.3b) | (106.1b) | (173.3b) | (96.5b) | (110.7b) | (113.4b) | (98.3b) | (135.1b) | (134.1b) |
Gross profit | 367.8b | 359.4b | 399.2b | 731.5b | 709.6b | 704.5b | 769.1b | 684.0b | 772.4b | 862.4b | 718.1b | 781.9b |
R&D expense | (72.0b) | (79.5b) | (77.5b) | (116.9b) | (113.5b) | (122.7b) | (106.8b) | (118.2b) | (117.6b) | (122.5b) | (131.6b) | (128.4b) |
JPY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Cash | 294.5b | 702.1b | 637.6b | 966.2b |
Accounts Receivable | 360.8b | 657.7b | 710.0b | 779.6b |
Inventories | 212.9b | 986.7b | 759.6b | 753.9b |
JPY | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 231.5b | 317.1b | 297.9b | 593.7b | 543.5b | 568.3b | 589.8b | 630.9b | 617.6b | 654.9b | 607.9b | 724.3b |
Accounts Receivable | 450.8b | 461.4b | 509.5b | 760.1b | 779.4b | 820.7b | 784.6b | 754.0b | 791.5b | 827.3b | 843.6b | 715.5b |
Inventories | 221.4b | 233.3b | 223.4b | 902.5b | 840.8b | 801.3b | 759.4b | 743.5b | 739.4b | 779.1b | 783.5b | 811.3b |
JPY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Net Income | 186.7b | 109.0b | 44.3b | 376.2b |
Depreciation and Amortization | 182.1b | 272.4b | 583.6b | 559.7b |
Inventories | 13.7b | 58.7b | 137.5b | 26.0b |
Accounts Payable | 6.9b | (16.4b) | (29.9b) | 36.6b |
JPY | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 78.1b | 126.5b | 164.4b | (20.6b) | 33.3b | 42.7b | 82.5b | 86.6b | 179.0b | 137.7b | 183.7b | 241.5b |
Depreciation and Amortization | 38.6b | 78.0b | 116.3b | 176.3b | 342.0b | 437.9b | 141.6b | 280.5b | 420.3b | 142.9b | 283.6b | 430.9b |
Inventories | (12.5b) | (21.5b) | (15.4b) | 52.6b | 71.0b | 92.7b | (4.4b) | 3.0b | 6.1b | (21.0b) | (25.0b) | (39.3b) |
Accounts Payable | (4.7b) | (230.0m) | 24.1b | (30.3b) | (41.5b) | (39.2b) | (23.2b) | (26.3b) | (5.1b) | (24.9b) | (9.0b) | (1.8b) |
JPY | FY, 2018 |
---|---|
EV/EBITDA | 1.6 x |
EV/EBIT | 15.5 x |
EV/CFO | 1.9 x |
Revenue/Employee | 65.0m |
Company Name | Date | Deal Size |
---|---|---|
PvP Biologics | February 26, 2020 | $330 m |
Shire | April 25, 2018 | $62 b |
TiGenix | January 05, 2018 | €520 m |
ARIAD Pharmaceuticals | January 09, 2017 | $5.2 b |
Inviragen | May 07, 2013 | |
LigoCyte Pharmaceuticals | October 05, 2012 | $60 m |
Intellikine | December 21, 2011 | $310 m |
Nycomed Pharma | May 19, 2011 | €9.6 b |
IDM Pharma , Inc. | June 24, 2009 | |
Millennium Pharmaceuticals | February 01, 2008 | $8.69 b |
Takeda Pharmaceutical revenue breakdown by business segment: 97.1% from ETHICAL DRUG and 2.9% from Other
A
76/100
A-
76/100
B+
75/100
A-
76/100
When was Takeda Pharmaceutical founded?
Takeda Pharmaceutical was founded in 1781.
Who are Takeda Pharmaceutical key executives?
Takeda Pharmaceutical's key executives are Andrew S. Plump, Christophe Weber and Costa Saroukos.
How many employees does Takeda Pharmaceutical have?
Takeda Pharmaceutical has 47,099 employees.
What is Takeda Pharmaceutical revenue?
Latest Takeda Pharmaceutical annual revenue is ¥3.2 t.
What is Takeda Pharmaceutical revenue per employee?
Latest Takeda Pharmaceutical revenue per employee is ¥67.9 m.
Who are Takeda Pharmaceutical competitors?
Competitors of Takeda Pharmaceutical include Nipro Corporation, Grifols and Codiak Biosciences.
Where is Takeda Pharmaceutical headquarters?
Takeda Pharmaceutical headquarters is located at 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo.
Where are Takeda Pharmaceutical offices?
Takeda Pharmaceutical has offices in Tokyo, Fujisawa, Fukuchiyama, Hikari and in 55 other locations.
How many offices does Takeda Pharmaceutical have?
Takeda Pharmaceutical has 61 offices.
Receive alerts for 300+ data fields across thousands of companies